OBALON THERPTCS (NASDAQ:OBLN) had its price target reduced by UBS AG from $20.00 to $16.00 in a report issued on Friday, www.benzinga.com reports. They currently have a buy rating on the stock.
A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of OBALON THERPTCS from a hold rating to a sell rating in a research note on Wednesday, November 8th. BTIG Research decreased their price objective on shares of OBALON THERPTCS from $20.00 to $15.00 and set a buy rating on the stock in a research note on Monday, November 6th. Finally, Northland Securities reissued a sell rating and issued a $4.00 price objective on shares of OBALON THERPTCS in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $13.00.
OBALON THERPTCS (OBLN) traded down $0.18 during midday trading on Friday, hitting $8.04. 30,700 shares of the stock were exchanged, compared to its average volume of 34,629. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.78 and a quick ratio of 8.65. OBALON THERPTCS has a 52 week low of $7.77 and a 52 week high of $13.18.
COPYRIGHT VIOLATION WARNING: “OBALON THERPTCS (OBLN) PT Lowered to $16.00 at UBS AG” was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/14/obalon-therptcs-obln-pt-lowered-to-16-00-at-ubs-ag.html.
Large investors have recently made changes to their positions in the stock. William Blair Investment Management LLC increased its stake in OBALON THERPTCS by 168.9% in the second quarter. William Blair Investment Management LLC now owns 329,643 shares of the company’s stock valued at $3,267,000 after acquiring an additional 207,041 shares during the last quarter. Wetherby Asset Management Inc. bought a new stake in shares of OBALON THERPTCS during the second quarter worth $238,000. Kornitzer Capital Management Inc. KS grew its stake in shares of OBALON THERPTCS by 0.5% during the second quarter. Kornitzer Capital Management Inc. KS now owns 422,410 shares of the company’s stock worth $4,186,000 after buying an additional 2,075 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of OBALON THERPTCS by 33.9% during the second quarter. Bank of New York Mellon Corp now owns 21,135 shares of the company’s stock worth $210,000 after buying an additional 5,353 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of OBALON THERPTCS by 90.8% during the first quarter. UBS Group AG now owns 11,856 shares of the company’s stock worth $127,000 after buying an additional 5,641 shares during the last quarter. 43.65% of the stock is currently owned by institutional investors and hedge funds.
About OBALON THERPTCS
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for OBALON THERPTCS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OBALON THERPTCS and related companies with MarketBeat.com's FREE daily email newsletter.